• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 19, 2024 at 11:22: AM
via
  • Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the “frenzy” of weight loss drugs.
  • CEO Vas Narasimhan said the company was researching treatments that deal with the secondary effects of weight loss, but that it does not plan to compete directly with Novo Nordisk and Eli Lilly.

article source
 




Top Bottom
Back
Quote